Metraipolis › archive › dc_fe009feb6e89

Sex-disparate safety profile of Obinutuzumab: a pharmacovigilance analysis using the FDA adverse event reporting system — Europe PMC PMID:41633312

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/41633312
DOI: 10.1016/j.clinsp.2026.100865
License (as archived): solo-consultazione
Archived: 2026-11-06T07:43:42.811Z
SHA-256 of the archived text: 71b2b87ecd6565d35338f840397ea88b0236a55afcb149a071aac1fa2f161435
Stable URL of this page: https://metraipolis.com/documento/dc_fe009feb6e89

How to cite

Sex-disparate safety profile of Obinutuzumab: a pharmacovigilance analysis using the FDA adverse event reporting system — Europe PMC PMID:41633312 — Europe PMC (en), https://europepmc.org/article/MED/41633312 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_fe009feb6e89 (Metraipolis archive dc_fe009feb6e89, sha256 71b2b87ecd6565d35338f840397ea88b0236a55afcb149a071aac1fa2f161435)

BibTeX

@misc{dcfe009feb6e89,
  title = {Sex-disparate safety profile of Obinutuzumab: a pharmacovigilance analysis using the FDA adverse event reporting system — Europe PMC PMID:41633312},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41633312},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_fe009feb6e89; sha256 71b2b87ecd6565d35338f840397ea88b0236a55afcb149a071aac1fa2f161435},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41633312. Agents can read the archived copy with the MCP tool read_document.